Eric Easom, CEO of AN2 Therapeutics
January 7, 2022 10:57 AM ESTUpdated 11:17 AM
Financing

Ana­cor vet­er­ans raise $80M in bid to tack­le rare lung dis­ease with boron-based in­hibitors

Paul Schloesser

Associate Editor

Af­ter start­ing up with a $12 mil­lion Se­ries A in 2019, Cal­i­for­nia out­fit AN2 Ther­a­peu­tics is­sued its first press re­lease in over 2 years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times